Anticipated $-0.41 EPS for Advaxis, Inc. (ADXS) on June, 5

May 17, 2018 - By Theresa Judd

Advaxis, Inc. (NASDAQ:ADXS) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.12. That’s change of 0.11, from 2017Q3’s 1.23. 17 investors sold all, 17 reduced holdings as Advaxis, Inc. ratio worsened. 22 rose positions while 16 funds took positions. Funds hold 15.17 million shares thus 10.45% less from 2017Q3’s 16.94 million shares.
American Intll Gru stated it has 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Citadel Ltd Liability Corporation holds 52,793 shs. Jane Street Grp Limited accumulated 11,428 shs. Moreover, State Board Of Administration Of Florida Retirement Systems has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 20,505 shs. California Public Employees Retirement invested in 0% or 47,900 shs. Jpmorgan Chase And invested in 8,027 shs or 0% of the stock. Moreover, Schwab Charles Inv Management Inc has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Barclays Public Ltd Company accumulated 26 shs. Morgan Stanley, New York-based fund reported 178,381 shs. Weiss Multi invested in 30,000 shs. Comml Bank Of America Corp De has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Citigroup Incorporated reported 6,404 shs. Tiaa Cref Invest Mgmt Limited Liability Corporation has 105,059 shs. California State Teachers Retirement Sys, a California-based fund reported 58,649 shs. Manufacturers Life Ins The owns 8,695 shs for 0% of their capital.

Advaxis, Inc. had 3 sales and 0 insider buys since December 29, 2017. This’s net activity of $20,259. On Friday, February 2 Shares for $94 were sold by LOMBARDO ANTHONY A. On Friday, December 29 $16,612 worth of stock was sold by Bonstein Sara.

Advaxis, Inc. (NASDAQ:ADXS) is expected to announce earnings on June, 5., as reported by RTT. Analysts predict 19.61 % diference or $-0.41 from the $-0.51 EPS from 2017. After $-0.49 earnings per share was published previous quarter, analysts now see EPS growth of -16.33 % for Advaxis, Inc.. ADXS reached $1.87 during the last trading session after $0.13 change.Advaxis, Inc. has volume of 753,197 shares. Since May 17, 2017 ADXS has declined 77.70% and is downtrending. ADXS underperformed the S&P 500 by 89.25%.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

In total 2 analysts cover Advaxis (NASDAQ:ADXS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:ADXS)’s analyst reports since December 27, 2017 according to StockzIntelligence Inc. On Wednesday, December 27 the stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Buy” rating by H.C. Wainwright. The stock rating was maintained by H.C. Wainwright with “Buy” on Wednesday, March 14. The company rating was maintained by Cantor Fitzgerald on Tuesday, March 13.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.The firm is worth $97.83 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer.Last it reported negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another two news for Advaxis, Inc. (NASDAQ:ADXS) were briefly announced by: on May 14, 2018 with title “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …”. The other‘s article was titled “Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy” and announced on May 11, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: